U.S. Stem Cell (OTCMKTS:USRM) posted its quarterly earnings results on Monday. The company reported $0.05 EPS for the quarter, reports. The business had revenue of $1.47 million during the quarter.

OTCMKTS USRM opened at $0.08 on Tuesday. U.S. Stem Cell has a one year low of $0.02 and a one year high of $0.13. The company has a current ratio of 0.18, a quick ratio of 0.17 and a debt-to-equity ratio of -0.32.

How to Become a New Pot Stock Millionaire

TRADEMARK VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2018/04/17/u-s-stem-cell-usrm-releases-quarterly-earnings-results.html.

U.S. Stem Cell Company Profile

U.S. Stem Cell, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for improving cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, lower limb ischemia, and rheumatoid arthritis.

Earnings History for U.S. Stem Cell (OTCMKTS:USRM)

Receive News & Ratings for U.S. Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for U.S. Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.